TRANILCIPROMINE ARISTO 10 mg FILM-COATED TABLETS

2. What you need to know before taking Tranilcipromina Aristo

Do not taketranilcipromina

• if you are allergic to tranilcipromina or to any of the other components of this medicine included in section 6;
• if you have hormone-producing tumors of the adrenal gland (pheochromocytoma);
• if you have a tumor, usually in the gastrointestinal tract area, that produces substances that increase blood pressure (carcinoid tumor);
• if you have diseases of the cerebral blood vessels (e.g., after a stroke);
• if you have vascular malformations such as dilations of the arterial blood vessels (aneurysms);
• if you have severe forms of hypertension or cardiovascular diseases;
• if you have liver failure or liver disease;
• if you have severe renal insufficiency or kidney disease;
• if you have metabolic disorders in the hematopoietic system (porphyria);
• if you have a disease characterized by increased urine excretion and increased thirst with increased fluid intake (diabetes insipidus);
• if you have malignant hyperthermia (a rare disease that can occur in relation to anesthesia), even if it occurred at an earlier time;
• if you present with a picture of acute confusion (delirium);
• if you present with acute intoxication with CNS depressant drugs (such as sleep inducers, analgesics, and psychotropic drugs like neuroleptics, antidepressants, lithium) and alcohol;
• if you have malignant hyperthermia (a rare disease that can occur in relation to anesthesia), even if it occurred before;
• if you are a child or adolescent (under 18 years old).

Do not take tranilcipromina if you are taking one of the following medicines at the same time:

• Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and other so-called "selective serotonin reuptake inhibitors" (a group of agents used to treat depression). There is a risk of triggering the so-called serotonin syndrome with symptoms such as involuntary and rhythmic contractions of the muscles, including the muscles that control eye movement, agitation, increased blood pressure, hallucinations, coma, excessive sweating, tremors, exaggerated reflexes, increased muscle tension, irritability, and increased body temperature above 38°C.
• Vortioxetine, an agent for the treatment of depression. There is a risk of serotonin syndrome (see first item).
• Venlafaxine, duloxetine, and milnacipran, agents for the treatment of depression. There is a risk of serotonin syndrome (see first item).
• Sibutramine, an agent for the treatment of overweight (which is no longer used today). There is a risk of serotonin syndrome (see first item).
• Clomipramine, an agent used to treat depression. There is a risk of serotonin syndrome (see first item).
• Sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, and other so-called "triptans", agents used to treat migraine. There is a risk of serotonin syndrome (see first item).
• L-tryptophan. Delirium symptoms may appear.
• Buspirone, an agent for the treatment of anxiety and agitation. A strong increase in blood pressure has been reported.
• Imipramine, an agent used to treat depression. Serious adverse effects such as irritability, coma, increased body temperature, convulsions, and large fluctuations in blood pressure, especially increased blood pressure, may occur.
• Certain agents to increase blood pressure, but which may also be contained in nasal remedies, cough suppressants, or anti-cold and appetite suppressants (the so-called indirect sympathomimetics, e.g., ephedrine, methylsulfate of amezinium, phenylpropanolamine, cathine, amfepramone, metamfepramone, and amphetamines, also known as "stimulant amines"). There is a risk of severe hypertensive crises, characterized by a sudden increase in blood pressure.
• Pethidine (agent for severe pain), tramadol (agent for moderate pain), and dextromethorphan (contained in cough suppressants). Life-threatening adverse effects in the central nervous system or life-threatening influences on respiratory and circulatory functions may occur.
• Disulfiram, a deterrent agent for alcohol consumption. Delirium is possible.
• Levodopa (agent for the treatment of Parkinson's disease), provided it is not combined with agents such as benserazide or carbidopa. There is a risk of uncontrolled increase in blood pressure.

Warnings and precautions

Consult your doctor or pharmacist before starting to take this medicine.

Special caution is required when taking this medicine,

• with food and drink. You must not consume foods, stimulants, or drinks with high levels of tyramine during a period of 1 day before treatment until 14 days after treatment with tranilcipromina, which is also known as a low-tyramine diet (see section 2, "Taking tranilcipromina with food, drinks, and alcohol"). You must also not drink any alcohol during treatment with tranilcipromina. Alcohol changes and increases the effect of tranilcipromina in an unpredictable way;
• if you have high or low blood pressure or if you have an overactive thyroid gland. In that case, you should inform your doctor. Then, your doctor will only use tranilcipromina under rigorous blood pressure control;
• if you notice a pathological increase in vitality with an elevated mood (manic episode). In that case, you should immediately inform your doctor or caregiver. If so, you must stop taking tranilcipromina. This also applies if depressive disorders are being treated in the course of other mental illnesses and if delusional ideas, hallucinations, and thought disorders occur;
• if you have improperly consumed drugs or alcohol in the past. In that case, you should inform your doctor;
• if you have or have had seizures or epilepsy. In that case, you should inform your doctor. It cannot be ruled out that tranilcipromina may cause seizures;
• if you have diabetes. In that case, you should inform your doctor. Treatment with tranilcipromina may reduce your blood sugar levels. The dose of insulin and the medication to be taken must then be adjusted. Your blood sugar levels must be monitored more frequently;
• if you have renal insufficiency. In that case, you should inform your doctor. There is not enough experience to treat patients with a disorder of renal function. Therefore, patients with severe renal dysfunction must not be treated with tranilcipromina. Patients with impaired renal function must be carefully monitored (see section 3, "How to take tranilcipromina").

Suicidal thoughts and worsening of depression

If you are depressed, you may sometimes have thoughts of harming or killing yourself (suicide). These thoughts can be stronger when you first start using antidepressants, as all these medicines take time to work, usually a couple of weeks, sometimes more.

It is more likely that such thoughts will occur

• if you have ever thought about taking your life or have thought about harming yourself before;
• if you are a young adult. The results of clinical trials have shown a higher risk of suicidal behavior in young adults up to 25 years old who suffer from a psychiatric illness and have been treated with an antidepressant.

If you ever have thoughts of harming or killing yourself, consult your doctor or go to the hospital immediately.

It may be helpful if you tell a friend or relative that you are depressed. Ask them to read this leaflet. Ask them to tell you if they think your depression is getting worse or if they are worried about changes in your behavior.

Elderly patients

If you are over 65 years old, your doctor will slowly increase the daily total dose, keep the dose as low as possible, and monitor your blood pressure regularly (see section 3, "Dose in elderly patients").

Children and adolescents

Tranilcipromina must not be used in children and young people.

Other medicines and Tranilcipromina

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Tranilcipromina must not be taken at the same time as certain medicines. Read section 2, "What you need to know before taking Tranilcipromina Aristo", carefully, especially the section "Do not take Tranilcipromina if you are taking one of the following medicines at the same time", and consult your doctor.

Also, notethat certain medicinesthat are incompatiblewith tranilcipromina require a treatment-free period. If you switchfrom another medicine to tranilcipromina, the treatment-free periodwith the previously used medicine is based on the time it takes for the active ingredient to be eliminated from the body. If you have recently finished a treatment with tranilcipromina, you must wait at least 14 days before you can start taking another medicine.

Increased risk of adverse effects of tranilcipromina

Avoid taking tranilcipromina at the same time as certain so-called direct sympathomimetics (e.g., those contained in medicines for circulatory problems, to relax bronchial muscles, or in nasal drops).

The combination with β2-selective sympathomimetics for inhalation is also not associated with any particular risk.

If you have persistent depression that has been treated with other medicines for the treatment of depression (tricyclic antidepressants, e.g., amitriptyline) without satisfactory improvement, your doctor may, in individual cases, administer an additional dose of tranilcipromina with a slow increase in the dose. However, this does not apply to clomipramine, imipramine, or antidepressants administered by infusion.

Tranilcipromina may increase the effect of other medicines and even increase the risk of adverse effects

The blood pressure-lowering effect of agents for hypertension (e.g., guanethidine, methyldopa) may be potentiated with tranilcipromina. However, in individual cases, an increase in blood pressure may also be triggered with states of excitement.

The effect of insulinand oral agents (agents that must be taken orally) against diabetes may be reinforced (see section 2, "Warnings and precautions").

The adverse effects of bupropionor anfebutamone(agent for smoking cessation), such as convulsions and states of excitement, may be intensified when taking tranilcipromina at the same time. Therefore, avoid this combination.

The effect of neuroleptics, antidepressants, benzodiazepines, and analgesics(medicines with a calming effect on the brain) may be potentiated when taking tranilcipromina at the same time.

In rare cases, the occurrence of serotonin syndrome has been reported with certain agents for the treatment of depression known to cause a potentially life-threatening serotonin syndrome and simultaneous treatment with buprenorphine (agent for severe pain). It cannot be ruled out that a serotonin syndrome may also occur with the simultaneous treatment of buprenorphineand tranilcipromina. The symptoms of serotonin syndrome are described in section 2 under the heading "Do not take tranilcipromina if you are taking one of the following medicines at the same time". Inform your doctor if you experience symptoms of a serotonin syndrome.

Interactions during surgery and dental treatment

If you are scheduled to undergo surgery with anestheticsand certain analgesics, the doctor must interrupt the administration of tranilcipromina 14 days before the operation. Interactions between medicines similar to tranilcipromina and anesthetics have been reported, which in some cases have been severe (e.g., unstable circulation, coma).

Please inform the anesthetist that you are taking this medicine before surgery. Pethidine, a strong analgesic used, for example, for postoperative pain therapy, must never be administered when being treated with tranilcipromina.

Inhalation anesthetics(volatile agents used to produce anesthesia) do not pose a greater risk for patients treated with this medicine than for any other patient under anesthesia. Ether is the only exception and, therefore, must not be used.

Local anesthetics:The generally low concentrations of adrenaline or noradrenaline in agents for local anesthesia, for example, in dental interventions or eye drops, do not pose a special risk for patients treated with tranilcipromina.

Note that this information may also apply to recently used medicines.

Taking tranilcipromina with food, drinks, and alcohol

When taking tranilcipromina, you must pay attention to the problemof biogenic amines(especially tyramine). Biogenic amines are natural ingredients in many foods. In most cases, their content in unprocessed animal and plant foods is very low. In contrast, certain processing methods involving microbiological transformations (e.g., fermentation in cheese production) can significantly increase the content of biogenic amines, but also as a result of storage at too high a temperature or spoilage.

In low concentrations, biogenic amines are not hazardous to humans, as the human body has enzymes (mono- and diamine oxidases) that break down the amines. However, the ingestion of higher concentrations of biogenic amines can produce a toxic effect (poisoning), especially if medicines like tranilcipromina with an amine oxidase-blocking effect are taken at the same time. The toxic effect of biogenic amines can manifest as nausea, vomiting, occipital headaches, and diseases of the nervous system, but above all as changes in blood pressure up to a marked increase in blood pressure (hypertensive crisis).

From one day before treatment with tranilcipromina, during treatment, and until 14 days after the last dose, you must avoid certain foods and drinks with a relatively high content of biogenic amines (e.g., air-dried, fermented, or aged meat, sausages, salami, fish or poultry, aged cheese, beans, fish sauces, all fermented soy products, yeast extracts, fermented beverages like beer or wine). This low-tyramine diet applies to all doses of tranilcipromina.

Please use all foodsas freshas possible. Consume raw or partially cooked foods on the day of preparation. Use opened semi-preserved foods and thawed frozen foods immediately. You can store opened preserves or fully cooked foods in the refrigerator for a maximum of 48 hours until consumption. Set your refrigerator to a low temperature of <4 °c if possible.< p>

At the end of the leaflet, you will find a list of allowed, prohibited, and allowed in small quantitiesfoods (according to their content of biogenic amines). Please note: only one food per meal is recommended, which is allowed in small quantities.

You must also not drink any alcoholduring treatment with this medicine. Alcohol changes and increases the effect of tranilcipromina in an unpredictable way.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Pregnancy

There is not enough experience with the use of tranilcipromina in pregnant women. This medicine may have negative effects on the fetus. Existing high blood pressure in the mother may be exacerbated, and a reduction in blood circulation in the placenta is possible.

Therefore, your doctor will only prescribe this medicine during pregnancy and especially in the first trimester of pregnancy if it is absolutely necessary. Tell your doctor immediately if you are planning to become pregnant or if you suspect you are pregnant. Your doctor may then switch to another medicine if necessary.

Breastfeeding

You must not take tranilcipromina during breastfeeding. If your doctor considers it necessary to use it during breastfeeding, you must stop breastfeeding.

Driving and using machines

Tranilcipromina has little or moderate influence on the ability to drive and use machines. Therefore, even when used as intended, and especially in the first few days of treatment, tranilcipromina may affect your ability to actively participate in road traffic and use machines. This is particularly true in combination with substances that act on the central nervous system. Remember that you must not drink alcohol during treatment with tranilcipromina!

During the first daysof treatment, you must not drivea caror other vehicles, nor use machines or electrical appliances, nor perform work that requires a lot of attention, e.g., those that are performed without a firm grip.

The decision will be made by your treating doctor in each case, taking into account your individual reaction and the dose.

Tranilcipromina contains lactose

This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.

3. How to take Tranilcipromina Aristo

Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

Unless the doctor prescribes otherwise, the usual dose is:

At the beginning of treatment, take 10 mg of tranilcipromine (corresponding to 1 film-coated tablet) once a day in the morning. Your doctor may increase this dose by 10 mg of tranilcipromine (corresponding to 1 film-coated tablet of Tranilcipromina 10 mg) per week until the adequate total daily dose for you is reached.

The recommended total daily dose is 20 mg to 40 mg of tranilcipromine (equivalent to 2 to 4 film-coated tablets of Tranilcipromina 10 mg).

Normally, the mood-elevating effects and relief of depression can be expected after 1 to 3 weeks. Your doctor will check the dose during therapy and adjust it if necessary.

If the disease does not respond adequately to the recommended total daily dose of 20 mg to 40 mg of tranilcipromine (corresponding to 2 to 4 film-coated tablets of Tranilcipromina 10 mg), your doctor may further increase the dose in hospital conditions in increments of 10 mg of tranilcipromine (corresponding to 1 film-coated tablet) per day every 1 to 3 weeks. The maximum total daily dose is 60 mg of tranilcipromine (corresponding to 6 film-coated tablets of Tranilcipromina 10 mg).

After improvement of the depressive disorder, your doctor may reduce the total daily dose to a maintenance dose of 10 mg to 20 mg of tranilcipromine (equivalent to 1 or 2 film-coated tablets of Tranilcipromina 10 mg).

Dose in elderly patients (over 65 years)

In the case of patients over 65 years, the attending physician will increase the dose more slowly under regular blood pressure control.

Patients with renal insufficiency

Patients with severe renal insufficiency should not be treated with this medication, as there is not enough therapeutic experience. If you have impaired renal function, your doctor will carefully monitor the treatment progress (see section 2. "Warnings and precautions").

Patients with hepatic insufficiency

Tranilcipromine should not be used to treat patients with hepatic insufficiency (see section 2. "Do not take tranilcipromine").

Use in children and adolescents

Tranilcipromine should not be used in children and adolescents (see section 2. "Do not take tranilcipromine").

Form of administration

The film-coated tablets are taken orally.

Take this medication exactly as your doctor has indicated. If you have doubts, consult your doctor or pharmacist.

Take the film-coated tablets with sufficient liquid, preferably a glass of water, and do not chew them.

The tablet can be divided into equal doses.

The total daily dose may be divided into 1 to 3 times. Do not take the last film-coated tablet of tranilcipromine later than 3 pm to avoid sleep disturbance.

Indications for facilitating division

Place the tablet on a firm and flat surface (with the score facing up). Use your thumbs or index fingers to press the tablet from above, on both sides of the score, to divide it into two parts.

Duration of treatment

The duration of a treatment period with tranilcipromine until improvement of a depressive disease is usually at least 4 to 6 weeks. Your doctor may continue treatment with tranilcipromine at a reduced dose for 4 to 6 months.

If you switch from another agent for the treatment of depression to tranilcipromine, your doctor will generally prescribe a treatment-free period of at least 7 days and will only prescribe 1 film-coated tablet of tranilcipromina 10 mg for at least the first week after starting treatment.

It is important not to stop treatment or change the dose without consulting your doctor.

Please consult your doctor or pharmacist if you consider that the effect of this medication is too strong or too weak.

If you take more Tranilcipromina than you should

Inform your doctor immediatelyso that they can decide what measureto take.

The signs of overdoseinclude confusion, overexcitement up to cerebral convulsive crises, obnubilation up to fainting, fever, deterioration of respiratory function (up to respiratory arrest) and of the cardiovascular system (intense fluctuations in blood pressure, irregular heartbeats) as well as of the muscles (strong muscle spasms).

In certain circumstances, the signs of an overdose may not appear until several hours after taking the tablets.

In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take tranilcipromina

Do not take a double dose to make up for forgotten doses. Continue taking the dose at the next scheduled time as prescribed.

If you interrupt treatment with tranilcipromina

Withdrawal symptoms such as anxiety, restlessness, sleep disturbances, stupor, or delirium may appear. Avoid suddenly interrupting long-term high-dose therapy with tranilcipromine. Always end therapy under medical supervision by gradually reducing the dose. Inform your doctor if you experience such withdrawal symptoms after reducing the dose or after stopping this medication. You may need to take the last dose again and then reduce the dose in smaller intervals.

If you have any doubts about taking this medication, consult your doctor or pharmacist.

4. Possible adverse effects

Like all medications, this medication can cause adverse effects, although not all people experience them.

If you experience an unusually elevated or irritable mood (manic disorder), do not continue taking this medication and consult your doctor as soon as possible.

Other adverse effects

The following adverse effects are very common, especially at the beginning of treatment: sleep disturbances, low blood pressure, decrease in blood pressure when standing up.

Very common:may affect more than 1 in 10 people:

• insomnia, sleep disturbances;
• decrease in blood pressure when standing up, low blood pressure.

Common:may affect up to 1 in 10 people:

• anxiety, hyperactivity, agitation;
• dizziness, dry mouth, fatigue;
• palpitations;
• high blood pressure (arterial hypertension);
• weight gain, weight loss, weakness.

Uncommon:may affect up to 1 in 100 people:

• severe increases in blood pressure (hypertensive crises), which may be accompanied by rapid heartbeats or palpitations, facial flushing, headaches (especially occipital headaches), neck stiffness, nausea, vomiting, and photophobia.

In individual cases, especially if dietary guidelines are not observed and there is a drug interaction with other medications, they can cause a hemorrhage in the cranial cavity (intracranial hemorrhage) (see section 2. "Taking tranilcipromine with food, drinks, and alcohol" or "Other medications and tranilcipromine").

Rare:may affect up to 1 in 1,000 people:

• anemia (low red blood cell count), reduction in the number of different cells in the blood;
• psychological dependence;
• cerebral convulsive crises;
• swelling due to tissue fluid accumulation (edema);
• constipation, diarrhea;
• sweating;
• muscle spasms, myalgias;
• abnormal orgasms, erectile dysfunction, ejaculation disorders;
• hallucinations, confusion (rare/very rare);
• neuralgias (polyneuropathies) (rare/very rare);
• blurred vision (rare/very rare);
• hepatic insufficiency, increased hepatic enzyme activity (rare/very rare);
• allergic skin rashes (rare/very rare);
• joint pain (rare/very rare);
• increased body temperature (rare/very rare).

Very rare:may affect up to 1 in 10,000 people:

• alopecia;
• increased release of the ADH hormone, which regulates water balance, with consequent reduction in urination.

Frequency not known:the frequency cannot be estimated from the available data

• suicidal thoughts, suicidal behavior*
  • Suicidal thoughts and behaviors have been reported during therapy with medications containing the same active ingredient as Tranilcipromina or shortly after ending treatment (see section 2. "Warnings and precautions").
• tremors, somnolence, and dizziness;
  • tinnitus;
  • nausea with or without vomiting and nonspecific gastrointestinal symptoms;
  • muscle contractions;
  • urinary disorders;
  • chest pain, feeling of cold, and fatigue.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for human use medications: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

5. Conservation of Tranilcipromina Aristo

Keep this medication out of sight and reach of children.

Do not use this medication after the expiration date that appears on the box and blister pack after "exp.". The expiration date is the last day of the month indicated.

Do not store at a temperature above 25°C.

Medications should not be thrown away through the sewage system or in the trash. Deposit the packaging and medications you no longer need in the SIGRE point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.

6. Contents of the pack and additional information

Composition of Tranilcipromina

• The active ingredient is tranilcipromina.

Each film-coated tablet contains 10 mg of tranilcipromina (as tranilcipromina sulfate).

• The other ingredients are:

Tablet core: lactose monohydrate, corn starch, microcrystalline cellulose, anhydrous colloidal silica.

Coating: poly(vinyl alcohol), Macrogol 3350, titanium dioxide, talc, yellow iron oxide (E 172), black iron oxide (E 172), carmine (E 132).

Appearance and pack contents of the product

Tranilcipromina Aristo 10 mg are film-coated tablets, green, round, with a break line and a score.

The tablet can be divided into equal doses.

Blister pack (PVC/PE/ACLAR with child-resistant aluminum foil or PVC/PVDC film with child-resistant aluminum foil).

Tranilcipromina Aristo 10 mg is available in packs of 30, 45, 50, 60, 90 and 100 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorisation holder and manufacturer

Aristo Pharma GmbH

Wallenroder Straße 8-10

13435 Berlin, Germany

For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:

Aristo Pharma Iberia, S.L.

C/ Solana, 26

28850, Torrejón de Ardoz

Madrid, Spain

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

Austria Tranylcypromin Aristo 10 mg Filmtabletten

Netherlands Tranylcypromine Aristo 10 mg filmomhulde tabletten

Spain Tranilcipromina Aristo 10 mg film-coated tablets

Date of last revision of this leaflet:10/2022

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Annex

Please note the following indication: take only one food per meal, which is allowed in small quantities.

The list is not exhaustive and regional specificities may apply.